Show simple item record

dc.contributor.authorVan Dyck, Walter
dc.contributor.authorNeels, Leo
dc.date.accessioned2017-12-02T14:52:49Z
dc.date.available2017-12-02T14:52:49Z
dc.date.issued2014
dc.identifier.urihttp://hdl.handle.net/20.500.12127/4997
dc.description.abstractIn the research-intensive pharmaceutical industry, two rationales for M&A prevail. First, deals may be intended to provide access to target companies’ markets or innovative treatments R&D programs and, second, economies of scale could boost cost-efficiency. Both rationales lead to increased valuation of the merged company. The $119 billion takeover approach by Pfizer, the largest drug maker in the world, was resisted by AstraZeneca, another pharmaceutical giant and crown jewel of the UK-based life sciences industry at an offer representing a 45% premium over its share price before Pfizer made its move public. What went wrong and do we see a fundamental trend towards more or maybe different M&A activity in the pharmaceutical industry?
dc.language.isoen
dc.subjectHealthcare
dc.subjectPharmaceutical Industry
dc.titleThe future of M&A in the pharmaceutical industry: Promoting or stifling innovation?
dc.identifier.journalFinance Monthly
dc.source.issueJune
dc.source.beginpage26
dc.source.endpage27
vlerick.knowledgedomainOperations & Supply Chain Management
vlerick.knowledgedomainSpecial Industries : Healthcare Management
vlerick.typearticleJournal article
vlerick.vlerickdepartmentTOM
dc.identifier.vperid165113
dc.identifier.vperid31183
dc.identifier.vpubid6203


This item appears in the following Collection(s)

Show simple item record